Leap Therapeutics, Inc. (LPTX)

NASDAQ: LPTX · IEX Real-Time Price · USD
2.79
+0.07 (2.57%)
At close: Dec 6, 2023, 4:00 PM
2.85
+0.06 (2.15%)
After-hours: Dec 6, 2023, 7:56 PM EST
2.57%
Market Cap 71.33M
Revenue (ttm) n/a
Net Income (ttm) -81.05M
Shares Out 25.57M
EPS (ttm) -5.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 266,714
Open 2.67
Previous Close 2.72
Day's Range 2.65 - 2.93
52-Week Range 1.24 - 10.20
Beta 0.66
Analysts Strong Buy
Price Target 14.13 (+406.45%)
Earnings Date Nov 13, 2023

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, I... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 44
Stock Exchange NASDAQ
Ticker Symbol LPTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LPTX stock is "Strong Buy." The 12-month stock price forecast is $14.13, which is an increase of 406.45% from the latest price.

Price Target
$14.13
(406.45% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

16 days ago - PRNewsWire

Leap Therapeutics Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

24 days ago - PRNewsWire

Leap Therapeutics to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

3 months ago - PRNewsWire

Leap Therapeutics Reports Second Quarter 2023 Financial Results

CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia...

4 months ago - PRNewsWire

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, ba...

5 months ago - PRNewsWire

Leap Therapeutics Announces Reverse Stock Split

CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it...

6 months ago - PRNewsWire

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overal...

6 months ago - PRNewsWire

Leap Therapeutics Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial...

7 months ago - PRNewsWire

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that ...

8 months ago - PRNewsWire

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

9 months ago - PRNewsWire

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotec...

9 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights...

11 months ago - PRNewsWire

Mergers and Acquisitions in 2023 Off To A Strong Start

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...

11 months ago - MarketBeat

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap sh...

11 months ago - Business Wire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating Leap Therapeutics, Inc. ("Leap") (NASDAQ: LPTX) regarding possible breaches of fiduciary duties and oth...

11 months ago - Newsfile Corp

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX

NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

11 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.

NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the ...

11 months ago - PRNewsWire

Leap Therapeutics Acquires Flame Biosciences

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-f...

11 months ago - PRNewsWire

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that D...

11 months ago - PRNewsWire

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Do...

1 year ago - PRNewsWire

Leap Therapeutics Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass. , Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financi...

1 year ago - PRNewsWire

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical tri...

1 year ago - PRNewsWire

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that ...

1 year ago - PRNewsWire

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that th...

1 year ago - PRNewsWire

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

CAMBRIDGE, Mass. , Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that D...

1 year ago - PRNewsWire